0
0
A recent large-scale study published in Clinical Infectious Diseases reveals that hospitalized patients with community-acquired pneumonia (CAP) treated with azithromycin in combination with beta-lactam antibiotics have significantly lower mortality rates compared to those receiving doxycycline with similar therapy.
The research, led by Dr. Yewande Odeyemi of the Mayo Clinic, analyzed data from 8,492 patients (median age 73; 54.3% male) who were hospitalized for pneumonia and received either azithromycin or doxycycline alongside beta-lactams for at least 48 hours. Using a retrospective matched cohort design, the study matched patients based on comorbidities, recent immunosuppressant use, and pneumonia severity index.
Key findings include:
-
Lower Mortality Rates: In-hospital mortality was significantly lower in the azithromycin group (odds ratio, 0.71; P = .005). The benefits extended to 30-day (hazard ratio [HR], 0.85; P = .041) and 90-day (HR, 0.83; P = .005) mortality rates.
-
More Hospital-Free Days: Patients treated with azithromycin experienced more days outside the hospital within 28 days of admission compared to those on doxycycline (adjusted estimate, 1.37; P < .001).
-
Improved Survival for Non-ICU Patients: Among patients not requiring intensive care within 24 hours of admission, azithromycin was associated with improved 90-day survival (adjusted HR, 0.85; P = .007).
“Given that we found a difference in clinical outcomes between azithromycin versus doxycycline with beta-lactam therapy, our observational study suggests a potential benefit with using azithromycin for CAP treatment in contrast to the limited evidence available,” the authors noted.
The study highlights the potential for azithromycin to serve as a preferred adjunct in pneumonia treatment protocols, though further research is needed to confirm these findings in broader populations.
Disclaimer:
This news article is based on a published observational study and is for informational purposes only. The findings should not be considered as definitive clinical guidance. Treatment decisions should always be made by qualified healthcare professionals based on individual patient needs and circumstances. The study was not a randomized controlled trial, and results may be influenced by factors not accounted for in the analysis.
